VTVT management to participate in September investor conferences
VTVT announced management will participate in September investor conferences. The company is advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D).
HIGH POINT, N.C., Sept.
02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
NASDAQ:VTVT, a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferen…